| 前收市價 | 0.4800 |
| 開市 | 0.4800 |
| 買盤 | 0.1200 |
| 賣出價 | 0.9000 |
| 拍板 | 185.00 |
| 到期日 | 2025-12-19 |
| 今日波幅 | 0.4800 - 0.4800 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 23 |
Insider MonkeyIs Merck & Co., Inc. (MRK) the Best Defensive Stock According to Reddit?
We recently compiled a list of the 10 Best Defensive Stocks According to Reddit. In this article, we will look at where Merck & Co., Inc. (NYSE:MRK) stands against the other defensive stocks. September is typically the worst month for the markets, however with a much anticipated rate cut, 2024 might be a different story. […]
Investing.com HK美股開市前：波音勁升4% 加密貨幣股上升 聚焦iPhone 16發佈會
Investing.com - 周一(9日)開市前，美國股指期貨上升，預示美股在上周大跌後，可能暫時反彈。不過，後市仍需關注本月稍晚的聯儲局議息會議。高盛發表報告指，預計美聯儲目前的基本情況是9月減息25點子，但如果就業市場惡化，則估計隨後會議或減息50點子。報告提到，美聯儲理事沃勒(Christopher Waller)近日表示，預期減息將會謹慎地進行，如果隨後的資料顯示勞動市場出現顯著惡化，美聯儲或會採取快速且強而有力的行動，而且在適當時候，他會主張「前置減息」。
BenzingaSummit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sunday, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc. The data was presented at the International Association for the Study of Lung Cancer’s 2024 World Conference on Lung Cancer. The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small
